GlassScriptPhysician profile
Catrinia Druen
NPI 1497161764
$6,058.27
in general payments reported to CMS, 2019-2025
36 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $432 · 2021: $708 · 2022: $775 · 2023: $1,250 · 2024: $960 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,350.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $702.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $647.22 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $502.50 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $421.16 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $413.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $396.65 | 2019-2025 | |
| Amgen INC. | $331.10 | 2019-2025 | Evenity, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $186.79 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $157.99 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $125.60 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Corium, LLC | $98.48 | 2023 | Azstarys |
| Allergan, INC. | $78.07 | 2020 | |
| Amarin Pharma, INC. | $74.19 | 2019-2021 | |
| Alkermes, INC. | $62.88 | 2023-2025 | Lybalvi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.85 | 2020-2021 | |
| Lundbeck LLC | $41.46 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $38.52 | 2021 | |
| Exact Sciences Corporation | $38.47 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $35.66 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $29.83 | 2020-2021 | |
| Indivior INC. | $28.20 | 2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $23.95 | 2019-2022 | |
| Harmony Biosciences LLC | $19.49 | 2023 | Wakix |
| Uswm, LLC | $19.26 | 2021 | |
| Corcept Therapeutics | $18.22 | 2025 | Korlym |
| Dexcom, INC. | $17.71 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2020 | |
| Radius Health, INC. | $16.86 | 2024 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $16.53 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.32 | 2021 | |
| Astellas Pharma US INC | $15.12 | 2025 | Veozah |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Medtronic, INC. | $14.46 | 2023 | Minimed 770g |
| Biohaven Pharmaceutical Holding Company LTD. | $14.10 | 2022 | |
| Athena Bioscience, LLC | $11.11 | 2024 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catrinia Druen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.